Drug Profile
Nicotine/mecamylamine-transdermal - Elan
Latest Information Update: 02 Aug 2002
Price :
$50
*
At a glance
- Originator Elan Corporation
- Class
- Mechanism of Action Nicotinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Smoking withdrawal
Most Recent Events
- 23 Jun 1999 New profile
- 23 Jun 1999 Phase-III clinical trials for Smoking withdrawal in USA (Transdermal)